Interleukin-32 monoclonal antibodies for Immunohistochemistry, Western blotting, and ELISA

被引:62
作者
Kim, Ki-Hong [1 ]
Shim, Jung-Hyun [1 ]
Seo, Eun-Hee [1 ]
Cho, Min-Chul [1 ]
Kang, Jung-Woo [1 ]
Kim, Soo-Hyun [2 ]
Yu, Dae-Yeul [3 ]
Song, Eun-Young [4 ]
Lee, Hee-Gu [4 ]
Sohn, Jung-Hoon [4 ]
Kim, JinMan [5 ]
Dinarello, Charles A. [6 ]
Yoon, Do-Young [1 ]
机构
[1] Konkuk Univ, Lab Cell & Immunobiochem, Dept Biosci & Biotechnol, Seoul 143701, South Korea
[2] Konkuk Univ, Dept Biomed Sci & Technol, Seoul 143701, South Korea
[3] Korea Res Inst Biosci & Biotechnol, Dis Model Res Ctr, Taejon 305805, South Korea
[4] Korea Res Inst Biosci & Biotechnol, Cell Res Ctr, Taejon 305805, South Korea
[5] Chungnam Natl Univ, Coll Med, Dept Pathol, Taejon 303131, South Korea
[6] Univ Colorado, Hlth Sci Ctr, Div Infect Dis, Denver, CO 80262 USA
关键词
IL-32; ELISA; monoclonal antibody; epitope;
D O I
10.1016/j.jim.2007.12.017
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The members of the IL-1 family play important roles in the development and pathogenesis of autoimmune and inflammatory diseases. Especially, IL-1 and IL-18 belong to the IL-1 family because they share structural similarity and require caspase-1 for processing. Currently, IL-18 has been studied for its biological effects in the broad spectrum of Th1- or Th2- related autoimmune diseases. IL-18 also uses a similar signaling pathway as that of IL-1 family members. Taken together these results, IL-18-inducible genes might also contribute to autoimmune and inflammatory diseases. It has recently been reported that an inducer of TNF-alpha. was identified as one of IL-18 inducible genes in IL-18 responsible cells and named as a new cytokine IL-32. We have produced novel monoclonal anti IL-32 antibodies in order to help study IL-32 function and to develop improved diagnosis of IL-32-expressing tumors. Several mAbs reactive to IL-32 isoforms were prepared and characterized by the epitope analysis and Western blotting performed using various deletion mutants and IL-32 isoforms (IL-32 alpha, beta, -gamma, and delta). In order to optimize the sandwich ELISA for IL-32, recombinant IL-32a was added, followed by the addition of a biotinylated mAb KU32-52 into the microliter plate wells pre-coated with a mAb KU32-07 or mAb KU32-56. The bound mAb was probed with a streptavidin conjugated to HRP. The epitope analysis and Western blot analysis revealed that mAb KU32-07 could detect only IL-32(x and KU32-52 was bound to all isoforms, whereas KU32-56 were reactive to IL-32 alpha, beta, delta isoforms but not gamma isoform. These sandwich ELISAs were highly specific and had a minimal detection limit of 80 pg/ml (mean+ 3 SD of zero calibrator) and measuring range of up to 3000 pg/ml. An ELISA using a coating mAb KU32-07 and a capturing biotinylated mAb KU32-52 had no cross-reaction with other cytokines such as IL-32 beta, IL-32 gamma, IL-32 delta, hIL-1 alpha, IL-1 beta, hIL-2, hIL-6, hIL-8, hIL-10, hIL-18, and hTNF-alpha. Intra-assay coefficients of variation were 11 to 6% (n=16) and inter-assay coefficients were 10 to 5% (n=9). Another ELISA using a coating mAb KU32-56 and a capturing biotinylated mAb KU32-52 detected both IL-32 alpha and IL-32 beta isoforms but not gamma and delta isoforms and had no cross-reaction with other cytokines such as WL-1 alpha, IL-1 beta, hIL-2, hIL-6, hIL-8, hIL-10, hIL-18, and hTNF-alpha. One mAb KU32-09 was shown to react strongly on immunohistochemistry. Our newly established mAbs, KU32-07, KU32-09, KU32-52, KU32-56, have different and useful properties for the detection of IL-32 by immunohistochemistry, ELISA, and Western blotting. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:38 / 50
页数:13
相关论文
共 24 条
[1]  
Ahn HJ, 1997, J IMMUNOL, V159, P2125
[2]   Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein [J].
Banda, NK ;
Vondracek, A ;
Kraus, D ;
Dinarello, CA ;
Kim, SH ;
Bendele, A ;
Senaldi, G ;
Arend, WP .
JOURNAL OF IMMUNOLOGY, 2003, 170 (04) :2100-2105
[3]   A newly defined interleukin-1? [J].
Bazan, JF ;
Timans, JC ;
Kastelein, RA .
NATURE, 1996, 379 (6566) :591-591
[4]  
Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO
[5]  
2-2
[6]   Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation [J].
Dinarello, CA .
CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (04) :378-385
[7]   Involvement of IL-32 in activation-induced cell death in T cells [J].
Goda, C ;
Kanaji, T ;
Kanaji, S ;
Tanaka, G ;
Arima, K ;
Ohno, S ;
Izuhara, K .
INTERNATIONAL IMMUNOLOGY, 2006, 18 (02) :233-240
[8]   Six months open label trial of leflunomide in active ankylosing spondylitis [J].
Haibel, H ;
Rudwaleit, M ;
Braun, J ;
Sieper, J .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (01) :124-126
[9]   Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra [J].
Hawkins, PN ;
Lachmann, HJ ;
Aganna, E ;
McDermott, MF .
ARTHRITIS AND RHEUMATISM, 2004, 50 (02) :607-612
[10]  
Hoshino T, 1999, J IMMUNOL, V162, P5070